Palantir Technologies lifts guidance after Q2 results beat Wall Street estimates
Mary Theresa Coelho, Executive Vice President and CFO of HOOKIPA Pharma Inc (NASDAQ:HOOK), sold 13,609 shares of common stock on July 22, 2025, at a price of $0.92, for a total transaction value of $12,520. The transaction comes as HOOKIPA’s stock has declined over 84% in the past year, with the company’s market capitalization currently standing at $12.2 million. According to InvestingPro analysis, the stock is currently trading below its Fair Value.
Following the transaction, Coelho directly owns 56,266 shares of HOOKIPA Pharma Inc. The sale was executed to cover tax obligations related to the vesting of restricted stock units. While the company maintains a strong current ratio of 3.61 and holds more cash than debt, InvestingPro data reveals the company is quickly burning through its cash reserves. For comprehensive insider trading analysis and 16 additional key insights about HOOKIPA, consider exploring the full Pro Research Report available on InvestingPro.
In other recent news, HOOKIPA Pharma Inc. announced its plan to voluntarily delist from the Nasdaq Capital Market. This decision is part of a strategic move following an asset purchase agreement with Gilead Sciences, Inc. (NASDAQ:GILD) Under this agreement, Gilead will acquire HOOKIPA’s assets related to its HB-400 hepatitis B virus program and certain assets from its HB-500 HIV program. These developments mark significant changes for HOOKIPA Pharma as it transitions its focus. The delisting process involves deregistering its common stock under the Securities Exchange Act of 1934. This move is expected to streamline the company’s operations following the asset sale. Investors and stakeholders are closely monitoring these transitions as they unfold.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.